A PYY compound having a maximum of 10 amino acid modifications as compared to hPYY (SEQ ID NO:2), wherein the PYY compound comprises i) lysine at the position corresponding to position 7 or 10 of hPYY (SEQ ID NO:1); ii) tryptophan at the position corresponding to position 30 of hPYY (SEQ ID NO:1); iii) leucine at the position corresponding to position 31 of hPYY (SEQ ID NO:1); iv) tyrosine at the position corresponding to position 28 of hPYY (SEQ ID NO:1) and/or isoleucine at the position corresponding to position 22 of hPYY (SEQ ID NO:1); and v) a modifying group attached to the epsilon amino group of said lysine at the position corresponding to position 7 or 10 of hPYY (SEQ ID NO:1), wherein said modifying group is defined by A- r -C- or A- r -C- w, wherein A- is selected from Chem. 1 and Chem. 2 Chem. 1: HOOC-(CH 2) p -CO-*, Chem. 2: HO 3 S-(CH 2) q -CO-* wherein p is an integer in the range of 14-18, and q is an integer in the range of 15-17; B- is Chem. 3 Chem. 3: *[NH-CH(COOH)-(CH 2) 2 -CO-]-*, r is an integer in the range of 1-3; w is an integer in the range of 1-3; and C- is absent or selected from Chem. 4 and Chem. 5 Chem. 4: *[NH-(CH 2) 2 -[O-(CH 2) 2] s -O-(CH 2) t -CO-] u -* Chem. 5: *[NH-(CH 2) v -CO-] x -* wherein s is an integer in the range of 1-3, t is an integer in the range of 1-3, u is an integer in the range of 1-4, v is an integer in the range of 3-7, and x is an integer in the range of 1-3; wherein * denotes the points of attachment, and wherein A, B, and C are interconnected via amide bonds and in the sequence indicated via said point of attachments; or a pharmaceutically acceptable salt, amide, or ester of said PYY compound; and wherein if the modifying group is A-B-C-B, C cannot be absent. i) lysine at the position corresponding to position 7 or 10 of hPYY (SEQ ID NO:1); ii) tryptophan at the position corresponding to position 30 of hPYY (SEQ ID NO:1); iii) leucine at the position corresponding to position 31 of hPYY (SEQ ID NO:1); iv) tyrosine at the position corresponding to position 28 of hPYY (SEQ ID NO:1) and/or isoleucine at the position corresponding to position 22 of hPYY (SEQ ID NO:1); and v) a modifying group attached to the epsilon amino group of said lysine at the position corresponding to position 7 or 10 of hPYY (SEQ ID NO:1), A- is selected from Chem. 1 and Chem. 2 Chem. 1: HOOC-(CH 2) p -CO-*, Chem. 2: HO 3 S-(CH 2) q -CO-* wherein p is an integer in the range of 14-18, and q is an integer in the range of 15-17; B- is Chem. 3 Chem. 3: *[NH-CH(COOH)-(CH 2) 2 -CO-]-*, r is an integer in the range of 1-3; w is an integer in the range of 1-3; and r is an integer in the range of 1-3; w is an integer in the range of 1-3; and C- is absent or selected from Chem. 4 and Chem. 5 Chem. 4: *[NH-(CH 2) 2 -[O-(CH 2) 2] s -O-(CH 2) t -CO-] u -* Chem. 5: *[NH-(CH 2) v -CO-] x -* wherein s is an integer in the range of 1-3, t is an integer in the range of 1-3, u is an integer in the range of 1-4, v is an integer in the range of 3-7, and x is an integer in the range of 1-3; wherein * denotes the points of attachment, and wherein A, B, and C are interconnected via amide bonds and in the sequence indicated via said point of attachments; or a pharmaceutically acceptable salt, amide, or ester of said PYY compound; and wherein if the modifying group is A-B-C-B, C cannot be absent. wherein s is an integer in the range of 1-3, t is an integer in the range of 1-3, u is an integer in the range of 1-4, v is an integer in the range of 3-7, and x is an integer in the range of 1-3; wherein * denotes the points of attachment, and wherein A, B, and C are interconnected via amide bonds and in the sequence indicated via said point of attachments; or a pharmaceutically acceptable salt, amide, or ester of said PYY compound; and wherein if the modifying group is A-B-C-B, C cannot be absent.